Our January 2023 roundup is upon us! We believe most viewers will get good value out of the first ~17:40 minutes of this video which includes an overview of Cassava Science’s ($SAVA) Phase 2 Alzheimer’s Top-Line Data (cognition only) and elucidation of Blarcamesine’s restorative neurogenesis abilities – partially by harnessing the power of the CDK5 gene. Beyond 17 minutes, viewers can get a more in-depth look at serotonin, as well as S1R enhancement in diabetes-induced dementia. My next video will likely be in mid-to-late February after an in-person interview with Dr. Timo Grimmer in Munich, Germany.
Link to CDK5 Article Discussed: https://pubmed.ncbi.nlm.nih.gov/34790098/
Link to Serotonin MCI article: https://pubmed.ncbi.nlm.nih.gov/36680976/
Spirit of the Coast Analytics strives to report medical intelligence pertaining to neurodegenerative & neurodevelopmental disorders to include Alzheimer’s Disease, Parkinson’s Disease, Rett Syndrome, Angelman Syndrome, Fragile X, and more.
We follow ongoing trends in clinical research, recap important peer-reviewed medical journals, and chronicle ongoing events at Anavex Life Sciences corp. ($AVXL), which we believe may have the most promising emerging therapeutics cross-central nervous system (CNS).
If you wish to learn more about Spirit of the Coast Analytics or leave a tip, more information is available at the link below.
Website Home: https://www.sotcanalytics.com/
If you wish to learn more about Anavex Life Sciences, more information is available at the links below.
Website Home: https://www.anavex.com/
Educational Video: https://www.anavex.com/vnrjune2022
00:00 Introduction
00:45 Cassava Sciences Phase 2 Alzheimer’s Data
05:45 Cassava Data Summary and Talking Points
08:38 CDK5 Protein & Blarcamesine Restorative Properties
11:35 CDK5, Glutamate, and Calcium Homeostasis
14:30 Serotonin and MCI
17:39 S1R Agonists and Effects on Diabetes-derived Cognitive Impairment
30:08 Article Summary, Dr. Grimmer Meet, and Closing
source
